Emergent BioSolutions (EBS) EBT (2016 - 2025)
Historic EBT for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $57.6 million.
- Emergent BioSolutions' EBT fell 5955.06% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.9 million, marking a year-over-year increase of 16236.75%. This contributed to the annual value of -$142.9 million for FY2024, which is 8045.68% up from last year.
- Per Emergent BioSolutions' latest filing, its EBT stood at $57.6 million for Q3 2025, which was down 5955.06% from -$16.8 million recorded in Q2 2025.
- In the past 5 years, Emergent BioSolutions' EBT ranged from a high of $256.3 million in Q4 2021 and a low of -$269.8 million during Q2 2024
- Its 5-year average for EBT is -$34.3 million, with a median of -$27.6 million in 2024.
- As far as peak fluctuations go, Emergent BioSolutions' EBT plummeted by 412631.58% in 2023, and later soared by 66611.57% in 2025.
- Quarter analysis of 5 years shows Emergent BioSolutions' EBT stood at $256.3 million in 2021, then crashed by 123.96% to -$61.4 million in 2022, then grew by 11.24% to -$54.5 million in 2023, then skyrocketed by 49.36% to -$27.6 million in 2024, then soared by 308.7% to $57.6 million in 2025.
- Its last three reported values are $57.6 million in Q3 2025, -$16.8 million for Q2 2025, and $92.7 million during Q1 2025.